Cyrus J. Lawrence LLC Raises Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cyrus J. Lawrence LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,436 shares of the medical research company’s stock after buying an additional 20 shares during the period. Cyrus J. Lawrence LLC’s holdings in Thermo Fisher Scientific were worth $7,429,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Accretive Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 8.1% in the fourth quarter. Accretive Wealth Partners LLC now owns 640 shares of the medical research company’s stock worth $340,000 after purchasing an additional 48 shares during the last quarter. Aveo Capital Partners LLC boosted its position in Thermo Fisher Scientific by 9.7% during the 4th quarter. Aveo Capital Partners LLC now owns 816 shares of the medical research company’s stock valued at $433,000 after buying an additional 72 shares during the period. Gryphon Financial Partners LLC increased its position in shares of Thermo Fisher Scientific by 8.5% in the fourth quarter. Gryphon Financial Partners LLC now owns 1,484 shares of the medical research company’s stock valued at $794,000 after acquiring an additional 116 shares during the period. TrinityPoint Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. TrinityPoint Wealth LLC now owns 4,080 shares of the medical research company’s stock valued at $2,166,000 after acquiring an additional 164 shares during the last quarter. Finally, Cape Investment Advisory Inc. grew its stake in shares of Thermo Fisher Scientific by 52.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock worth $40,000 after purchasing an additional 26 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the subject of several research analyst reports. TD Cowen increased their price objective on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Wells Fargo & Company started coverage on Thermo Fisher Scientific in a research report on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price objective on the stock. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. Raymond James increased their price objective on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Finally, Robert W. Baird upped their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $647.78.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Lisa P. Britt sold 3,624 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the transaction, the vice president now owns 13,699 shares in the company, valued at approximately $8,397,760.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,084 shares of company stock worth $14,094,292. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 1.1 %

TMO stock opened at $613.69 on Monday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $627.88. The stock has a market capitalization of $234.26 billion, a P/E ratio of 39.36, a P/E/G ratio of 2.86 and a beta of 0.78. The business has a fifty day moving average price of $599.56 and a 200-day moving average price of $581.38.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter in the prior year, the business earned $5.15 EPS. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.